Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 25, 24 | 0.99 Decreased by -8.33% | 1.20 Decreased by -17.50% |
| Apr 25, 24 | 1.03 Increased by +7.29% | 1.22 Decreased by -15.57% |
| Feb 8, 24 | 0.73 Increased by +5.80% | 0.79 Decreased by -7.59% |
| Nov 9, 23 | 0.87 Increased by +3.57% | 0.85 Increased by +2.35% |
| Jul 28, 23 | 1.08 Increased by +25.58% | 0.95 Increased by +13.68% |
| Apr 27, 23 | 0.96 Increased by +1.05% | 1.07 Decreased by -10.28% |
| Feb 9, 23 | 0.69 Decreased by -17.86% | 0.67 Increased by +2.99% |
| Nov 10, 22 | 0.84 Increased by +55.56% | 0.72 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 13.56 B Increased by +18.04% | 1.43 B Increased by +4.00% | Increased by +10.53% Decreased by -11.89% |
| Jun 30, 24 | 12.94 B Increased by +13.33% | 1.93 B Increased by +6.00% | Increased by +14.89% Decreased by -6.47% |
| Mar 31, 24 | 12.94 B Increased by +18.93% | 1.93 B Increased by +6.88% | Increased by +14.89% Decreased by -10.13% |
| Dec 31, 23 | 12.68 B Increased by +13.13% | 2.18 B Increased by +141.84% | Increased by +17.19% Increased by +113.77% |
| Sep 30, 23 | 11.49 B Increased by +4.64% | 1.37 B Decreased by -16.22% | Increased by +11.96% Decreased by -19.94% |
| Jun 30, 23 | 11.42 B Increased by +5.99% | 1.82 B Increased by +405.00% | Increased by +15.93% Increased by +376.47% |
| Mar 31, 23 | 10.88 B Decreased by -4.49% | 1.80 B Increased by +367.10% | Increased by +16.57% Increased by +389.04% |
| Dec 31, 22 | 11.21 B Decreased by -6.69% | 901.00 M Increased by +359.65% | Increased by +8.04% Increased by +378.28% |